Trial Profile
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2010 Actual end date (1 Apr 2009) added as reported by ClinicalTrials.gov.
- 24 Mar 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.
- 24 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.